Detalhe da pesquisa
1.
Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission.
Blood
; 143(5): 417-421, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37879077
2.
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL.
Blood
; 2024 Mar 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38551807
3.
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia.
Cancer
; 2024 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38591430
4.
Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents.
Br J Haematol
; 204(3): 898-909, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37946611
5.
Aleukemic Chronic Myeloid Leukemia Without Neutrophilia and Thrombocytosis: A Report From the BCR::ABL1 Pathology Group.
Mod Pathol
; 37(2): 100406, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38104892
6.
TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia.
Blood
; 140(1): 58-72, 2022 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35390143
7.
The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis.
Blood
; 140(20): 2101-2112, 2022 11 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35877996
8.
Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia.
Blood
; 139(12): 1908-1919, 2022 03 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34914826
9.
Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia.
Blood
; 139(24): 3519-3531, 2022 06 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-35192684
10.
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.
Blood
; 140(11): 1200-1228, 2022 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35767897
11.
Outcomes and genetic dynamics of acute myeloid leukemia at first relapse.
Haematologica
; 2024 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38695144
12.
Ponatinib-review of historical development, current status, and future research.
Am J Hematol
; 2024 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38727135
13.
Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups.
Am J Hematol
; 99(4): 792-796, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38361282
14.
Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trial.
Am J Hematol
; 99(5): 836-843, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38400519
15.
Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia.
Am J Hematol
; 99(4): 586-595, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38317420
16.
Failure of treatment-free remission after a prolonged deep molecular response in patients with chronic myeloid leukemia.
Acta Haematol
; 2024 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38574468
17.
Validation of a Costing Algorithm and Cost Drivers for Neonates Admitted to the Neonatal Intensive Care Unit.
Am J Perinatol
; 2024 Feb 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38262468
18.
Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
JAMA
; 2024 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38722621
19.
Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy-The Surveillance, Epidemiology, and End Results database, 2000-2019.
Cancer
; 129(23): 3805-3814, 2023 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37769040
20.
A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies.
Cancer
; 129(4): 580-589, 2023 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36448227